Asthma

An APP forum discusses navigating a complex biologic landscape with significant administrative, access, and patient education responsibilities that physicians may encounter less directly.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.

Periconception eosinophils may serve as a biomarker to identify asthma risk in gestation, according to Christian Cardillo, MD, who presented late-breaking data at ATS 2026.

A study presented at the ATS 2026 found the New York City Housing Authority’s Mold Busters program was associated with nearly 2800 fewer annual asthma-related ED visits.

Clinicians at ATS 2026 will see late-breaking COPD, asthma, and pulmonary hypertension data alongside exclusive interviews with leading experts in respiratory medicine.

Black Americans bear a disproportionate burden of asthma mortality, and clinicians and policymakers must address a number of factors to make meaningful progress.

The FDA has approved budesonide/glycopyrrolate/formoterol fumarate as the first single-inhaler triple therapy for asthma.

Twin phase 3 trials show triple therapy with budesonide–glycopyrronium–formoterol improves FEV1 and lowers severe exacerbation rates in patients with uncontrolled asthma on ICS–LABA

In an interview, Bérard discusses cohort data showing no increased risk of major congenital malformations with ICS or ICS/LABA use in first trimester.

In an interview, Bérard discusses population-based data showing no increased risk of major congenital malformations with first-trimester asthma controller use.

Stay updated with the latest healthcare breakthroughs, including FDA actions, in this week’s essential news roundup.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

Sanofi’s dual TSLP/IL‑13 bispecific cuts asthma exacerbations and shrinks nasal polyps, while atopic dermatitis results disappoint.

The Q1 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

March 2026 saw new data from pivotal clinical trials and new expert conversations on HCPLive.

New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.

Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.

February 2026 saw new data and expert interviews from AAAAI 2026.

Using race-neutral spirometry equations such as GLI 2012 and GLI 2022 may improve diagnostic accuracy and reduce disparities in lung disease assessment.

Nguyen discussed how her study findings can help alleviate inhaled corticosteroid hesitancy for families.

Nguyen emphasized the safety of inhaled corticosteroids vs SABA-only therapy in pediatric asthma.